More cancer drugs in insurance list
Print Edition
In an effort to reduce the burden on patients, China is considering adding more anti-cancer drugs to its list of medicines eligible for medical insurance reimbursement.
Apart from cancer drugs, medicines for rare diseases, chronic illness, children and first-aid treatment are among the options for an enlarged reimbursement list, the National Healthcare Security Administration said in a document aimed at expanding medical insurance coverage.
The candidates for inclusion should be drugs that have been launched in the market with the approval of the National Medical Products Administration before December 31, 2018, said the document.
The existing medicines for reimbursement that have been banned from production, sales and use by national drug regulators should be excluded from the list, it said, with a new list to be released in June 2019.
In October 2018, 17 anti-cancer drugs were included in the medical insurance reimbursement list, with their prices cut by 56.7 percent on average.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
